BREAKING NEWS

Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug

Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug
FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith -
Copyright
Robert Galbraith(Reuters)
Text size Aa Aa

(Reuters) – Amgen Inc <AMGN.O> on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion (£10.3 billion)acquisition of Celgene Corp’s psoriasis therapy Otezla.

Bristol-Myers Squibb Co <BMY.N>, which completed its buyout of Celgene on Wednesday, had agreed to divest the drug for the merger to go through.

Amgen now expects 2019 adjusted earnings per share between $14.50 and $14.70, up from its prior range of $14.20 to $14.45.

Full-year revenue is now expected between $23.1 billion and $23.3 billion, compared with the previous range of $22.8 billion to $23.0 billion.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.
Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.